Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX – Get Rating) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 105,100 shares, a decline of 35.4% from the April 30th total of 162,700 shares. Based on an average daily trading volume, of 169,900 shares, the days-to-cover […]
/PRNewswire/ Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national.
/PRNewswire/ Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Entasis Therapeutics.
/PRNewswire/ Rowley Law PLLC is investigating potential securities law violations by Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) and its board of.